menu
    • menu

    Company profile for Valneva

    NEW Drugs in Dev: 18
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19 and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ValnevaFrance Flag
    Country
    Country
    France
    Address
    Address
    6 rue Alain Bombard, 44800 Saint-Herblain
    Telephone
    Telephone
    +33 2 28 07 37 10
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://valneva.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/valneva/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/valnevase

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    IMCAS World Congress

    IMCAS World Congress

    Not Confirmed

    envelop Contact Supplier

    IMCAS World Congress

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Valneva Pulls Chikungunya Vaccine Ixchiq In US
    Valneva Pulls Chikungunya Vaccine Ixchiq In US

    20 Jan 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/valneva-withdraws-chikungunya-vaccine-ixchiq-us-amid-new-fda-investigation

    FIERCE PHARMA
    20 Jan 2026
    Share Share
    Valneva Provides Update On Chikungunya Vaccine IXCHIQ
    Valneva Provides Update On Chikungunya Vaccine IXCHIQ

    19 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/19/3221191/0/en/Valneva-Provides-Update-on-Chikungunya-Vaccine-IXCHIQ.html

    GLOBENEWSWIRE
    19 Jan 2026
    Share Share
    Valneva To Present At J.P. Morgan Healthcare Conference
    Valneva To Present At J.P. Morgan Healthcare Conference

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3215888/0/en/Valneva-to-Meet-with-Investors-during-the-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share
    Valneva SE: Voting Rights Declaration - Dec 2025
    Valneva SE: Voting Rights Declaration - Dec 2025

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215697/0/en/Valneva-SE-Declaration-of-voting-rights-December-2025.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    Valneva, Serum Institute End Chikungunya Vaccine License Deal
    Valneva, Serum Institute End Chikungunya Vaccine License Deal

    31 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/31/3211836/0/en/Valneva-and-Serum-Institute-of-India-Announce-Discontinuation-of-Chikungunya-Vaccine-License-Agreement.html

    GLOBENEWSWIRE
    31 Dec 2025
    Share Share
    Valneva's Chikungunya Vaccine IXCHIQ Shows Strong Safety
    Valneva's Chikungunya Vaccine IXCHIQ Shows Strong Safety

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203393/0/en/Valneva-Reports-Positive-Final-Phase-2-Antibody-Persistence-and-Safety-Results-in-Children-for-its-Chikungunya-Vaccine-IXCHIQ.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search